Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 7/20 | 0.86 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.86 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.86 |
| ▸ | HTR1A | P08908 | 5/20 | 0.86 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.86 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.86 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.86 |
| ▸ | DRD1 | P21728 | 5/20 | 0.86 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.86 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.86 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.86 |
| ▸ | DRD3 | P35462 | 5/20 | 0.86 |
| ▸ | THPO | P40225 | 5/20 | 0.86 |
| ▸ | MTOR | P42345 | 5/20 | 0.86 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.86 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.86 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.86 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.86 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.86 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triflupromazine SCHEMBL32668886 | 0.93 | CYP1A2 (1.00) | TP53MAPK1CYP1A2HTR1AADRA2A | |
| Triflupromazine SCHEMBL44085 | 0.93 | CYP1A2 (1.00) | TP53MAPK1CYP1A2HTR1AADRA2A | |
| Triflupromazine SCHEMBL317144 | 0.91 | LMNA (1.00) | TP53MAPK1CYP1A2HTR1AADRA2A | |
| Triflupromazine SCHEMBL29419087 | 0.91 | LMNA (1.00) | TP53MAPK1CYP1A2HTR1AADRA2A | |
| Triflupromazine SCHEMBL30903901 | 0.91 | LMNA (1.00) | TP53MAPK1CYP1A2HTR1AADRA2A | |
| Triflupromazine SCHEMBL317145 | 0.90 | CYP1A2 (0.95) | TP53MAPK1CYP1A2HTR1AADRA2A | |
| SCHEMBL7750160 | 0.90 | TP53 (0.91) | TP53MAPK1CYP1A2HTR1AADRA2A | |
| SCHEMBL10168901 | 0.88 | FPR2 (0.80) | TP53MAPK1CYP1A2HTR1AADRA2A | |
| SCHEMBL30612615 | 0.88 | FPR2 (0.80) | TP53MAPK1CYP1A2HTR1AADRA2A | |
| SCHEMBL13305160 | 0.88 | TP53 (0.71) | TP53MAPK1CYP1A2HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012217-B2 | Benzimidazole compounds differentiate a mammalian stem cell into mesodermal or cardiomyocyte cells | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012217-B2 | Benzimidazole compounds differentiate a mammalian stem cell into mesodermal or cardiomyocyte cells | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2015-04-21 | — | — | US | disclosed |
| US-20100159596-A1 | SMALL MOLECULE COMPOUNDS FOR STEM CELL DIFFERENTIATION | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100159596-A1 | SMALL MOLECULE COMPOUNDS FOR STEM CELL DIFFERENTIATION | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-06-24 | — | — | US | disclosed |
| US-4833138-A | Phenothiazinealkaneamines for treatment of neurotoxic injury | WASHINGTON UNIVERSITY (US) | 1989-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100159596-A1 | SMALL MOLECULE COMPOUNDS FOR STEM CELL DIFFERENTIATION | RCOR3, BRD3, BRPF3 | TP53 199/4885MAPK1 1810/4885CYP1A2 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.